Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol Moreno

Showing results (131-140 of 167) with videos related to

Pageof 17
Sort By:
Haematologica|August 16, 2019
A cross-trial comparison of single-agent ibrutinib <i>versus</i> chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphomaAlessandra Tedeschi, Richard Greil, Fatih Demirkan, et al.
Leukemia & Lymphoma|April 5, 2017
FcγRIIb expression in early stage chronic lymphocytic leukemiaRosa Bosch, Alba Mora, Eva Puy Vicente, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 1, 2018
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell LymphomaSusan O'Brien, Peter Hillmen, Steven Coutre, et al.
Blood|September 21, 2006
Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlationsKostas Stamatopoulos, Chrysoula Belessi, Carol Moreno, et al.
NEJM Evidence|February 6, 2024
Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and ComorbiditiesArnon P Kater, Carolyn Owen, Carol Moreno, et al.
Haematologica|June 9, 2018
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2Paul M Barr, Tadeusz Robak, Carolyn Owen, et al.
Blood Advances|June 15, 2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studiesSteven E Coutre, John C Byrd, Peter Hillmen, et al.
Blood|February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohortConstantine S Tam, John N Allan, Tanya Siddiqi, et al.
European Journal of Heart Failure|November 20, 2021
Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trialJaved Butler, Stefan D Anker, Tariq Jamal Siddiqi, et al.
American Journal of Hematology|September 13, 2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer R Brown, Susan O'Brien, et al.
Pageof 17

Showing results (131-140 of 167) with videos related to

Sort By:
Pageof 17
Haematologica|August 16, 2019
A cross-trial comparison of single-agent ibrutinib <i>versus</i> chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphomaAlessandra Tedeschi, Richard Greil, Fatih Demirkan, et al.
Leukemia & Lymphoma|April 5, 2017
FcγRIIb expression in early stage chronic lymphocytic leukemiaRosa Bosch, Alba Mora, Eva Puy Vicente, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 1, 2018
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell LymphomaSusan O'Brien, Peter Hillmen, Steven Coutre, et al.
Blood|September 21, 2006
Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlationsKostas Stamatopoulos, Chrysoula Belessi, Carol Moreno, et al.
NEJM Evidence|February 6, 2024
Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and ComorbiditiesArnon P Kater, Carolyn Owen, Carol Moreno, et al.
Haematologica|June 9, 2018
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2Paul M Barr, Tadeusz Robak, Carolyn Owen, et al.
Blood Advances|June 15, 2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studiesSteven E Coutre, John C Byrd, Peter Hillmen, et al.
Blood|February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohortConstantine S Tam, John N Allan, Tanya Siddiqi, et al.
European Journal of Heart Failure|November 20, 2021
Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trialJaved Butler, Stefan D Anker, Tariq Jamal Siddiqi, et al.
American Journal of Hematology|September 13, 2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer R Brown, Susan O'Brien, et al.
Pageof 17